A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00375596
(Study withdrawn without starting or enrolling subjects due to a business decision to not proceed with the project.)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
6 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Be at least 6 years of age, of any race, or either gender.
Have a positive allergic history of ocular allergies and a positive skin test reaction to cat hair/dander, ragweed, tree and/or grass pollen within the past 24 months.
Have a calculated best-corrected visual acuity of 0.6 logMar or better in each eye as measured using an ETDRS chart.
Positive bilateral CAC reaction at Visit 1 & 2.
Have any known contraindications, allergies, or sensitivities to the use of any of the study medications, or their components.
Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters
Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye at the baseline slit-lamp exam of any visit